We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00214656
Recruitment Status : Unknown
Verified September 2005 by Austin Health.
Recruitment status was:  Recruiting
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
Sponsor:
Information provided by:
Austin Health

Brief Summary:

Aims and Hypotheses:

This randomised placebo controlled study will test the hypothesis that Recombinant Activated Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional therapy in complex cardiac surgery.

Major bleeding is still of concern in complex cardiac surgery. It has been shown to be associated with poorer patient outcome and results in the consumption of resources (hospital costs, manpower and blood bank reserves). This study has the potential to provide evidence that rVIIa can reduce transfusion requirements and improve patient outcome in a problematic aspect of complicated cardiac surgery.

The objective is to conduct a multi-centre randomised placebo controlled study that has been designed to scientifically evaluate the treatment of post bypass coagulopathy in the association with complex cardiac surgery. The trial design is based on clinical practice that has evolved over 2 years at the Austin Hospital during which 38 patients have received open label administration of rVIIa. There is currently no published RCT in this area and there is no TGA approval for the use of rVIIa for this indication.


Condition or disease Intervention/treatment Phase
Myocardial Ischemia Blood Coagulation Disorders Coronary Artery Disease Heart Valve Diseases Drug: Recombinant Activated Factor VII Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial
Study Start Date : June 2005
Estimated Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery
U.S. FDA Resources




Primary Outcome Measures :
  1. Adequate haemostasis to enable chest closure after administration of trial medication without the need for further intervention to improve coagulation.

Secondary Outcome Measures :
  1. Percentage of cases that haemostasis after first administration of coagulation factors alone
  2. Assessment of surgical field after administration of trial medication
  3. Time to closure of chest after administration of trial medication
  4. Transfusion requirements in post bypass period in theatre
  5. Transfusion requirements in ICU first 12 hours
  6. Mediastinal drainage in ICU first 12 hours
  7. Coagulation study results at various sample times
  8. Requirement for chest re-exploration
  9. Ventilation duration in ICU
  10. Duration of stay in ICU


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with scheduled cardiac surgery undergoing the following procedures
  • Double valve replacements or repair.
  • Major thoracic aortic surgery including hypothermic circulatory arrest or descending aortic reconstruction.
  • Valve repair or replacement in the setting of endocarditis
  • Complex procedures requiring cardiopulmonary bypass duration anticipated to exceed 180 minutes in patients aged ³70 years

Exclusion Criteria:

  • Patient unable to give informed consent
  • Patient refusal
  • Allergy to rVIIa
  • Allergy to aprotinin or prior exposure within 6 months
  • Pre-existing congenital coagulopathy
  • Pre-existing hypercoagulable state
  • Patients in inclusion criteria whose actual bypass time does not exceed 180 minutes
  • Unresolved surgical bleeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214656


Contacts
Contact: Peter McCall, FANZCA 61 3 94965000 ext 3800 peter.mccall@austin.org.au
Contact: stephanie j Poustie, MPH 61 3 94965000 ext 3800 stephanie.poustie@austin.org.au

Locations
Australia, Victoria
Austin Health Recruiting
Melbourne, Victoria, Australia, 3084
Contact: Peter McCall, FANZCA    61 3 94965000 ext 3800    peter.mccall@austin.org.au   
Contact: Stephanie J Poustie, MPH    61 3 94965000 ext 3800    stephanie.poustie@austin.org.au   
Principal Investigator: Peter McCall, FANZCA         
Sponsors and Collaborators
Austin Health
Investigators
Principal Investigator: Peter McCall, FANZCA Staff Anaesthetist

Publications:
ClinicalTrials.gov Identifier: NCT00214656     History of Changes
Other Study ID Numbers: H2005/02047
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: September 22, 2005
Last Verified: September 2005

Keywords provided by Austin Health:
Cardiac surgical procedures
Surgical blood loss
Surgical haemostasis
Factor VIIa
Anaesthesia

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Ischemia
Heart Valve Diseases
Blood Coagulation Disorders
Hemostatic Disorders
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Pathologic Processes
Hematologic Diseases
Hemorrhagic Disorders